Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 88Gynecologic 3Thoracic 2Sarcoma 2Head & Neck 2Genitourinary 2Breast 2

Conditions

Carcinoma, Non-Small-Cell Lung 41Colorectal Neoplasms 15Lung Neoplasms 12Ovarian Neoplasms 6Stomach Neoplasms 5Pancreatic Neoplasms 5Neoplasms 5Rectal Neoplasms 4Neoplasm Metastasis 4Melanoma 4Colonic Neoplasms 4Carcinoma, Renal Cell 4Triple Negative Breast Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Small Cell Lung Carcinoma 3Recurrence 3Mesothelioma 3Carcinoma, Pancreatic Ductal 3Peritoneal Neoplasms 2Fallopian Tube Neoplasms 2Esophageal Neoplasms 2Endometrial Neoplasms 2Breast Neoplasms 2Vipoma 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Spinocerebellar Degenerations 1Somatostatinoma 1Skin Neoplasms 1

Interventions

pembrolizumab 24Magnetic Resonance Spectroscopy 10Carboplatin 8Nivolumab 7Docetaxel 7Paclitaxel 6Gemcitabine 6Trastuzumab 5Taxes 5Fluorouracil 5Fluorodeoxyglucose F18 5Drug Therapy 5Cyclophosphamide 5Cisplatin 5fludarabine 4X-Rays 4Specimen Handling 4Radiotherapy 4Psychiatric Rehabilitation 4Polymerase Chain Reaction 4Leucovorin 4Injections 4durvalumab 3atezolizumab 3Surveys and Questionnaires 3Standard of Care 3Irinotecan 3Immunohistochemistry 3Gene Expression Profiling 3Early Intervention, Educational 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Esophageal Neoplasms × Oxaliplatin × Thoracic × Clear all
NCT06607185 2026-05-26

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

Eli Lilly and Company

Phase 1 Active not recruiting
750 enrolled
GastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT05891171 2026-03-31

ARC-25

Arcus Biosciences, Inc.

Phase 1 Active not recruiting
40 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡